Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
Real-Life Tacrolimus Levels Are Associated with Biopsy-Proven Acute Rejection After the First Year Post-Kidney Transplantation
Reduced Dose Mycophenolate Does Not Increase the Risk of Rejection Following Renal Transplantation
The Promise Of Tolerance In Living Donor Kidney Transplant (LDKT): A Retrospective, Real-world Assessment Of The Safety And Efficacy Of LDKT With FCR001 Investigational Cell-therapy Compared With Standard Of Care (SOC)
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients
The Role of Gut Microbiota in Tacrolimus Blood Level Fluctuation, Time in Therapeutic Range and AlloSure Donor Derived Cell-Free DNA, Controlling for CYP3A5
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
Use of De Novo mTOR Inhibitors in Highly Sensitized Kidney Transplant Recipients
2022 American Transplant Congress